QPS

CUSTOM-BUILT RESEARCH™

A flexible approach to Bioanalysis

WHETHER YOUR FOCUS IS SMALL MOLECULES, PROTEIN BIOTHERAPEUTICS, Vaccines or Gene Therapy, QPS provides a full range of bioanalytical solutions to support drug development from drug discovery through clinical development and regulatory filing.

TIME IS OF THE ESSENCE IN DRUG DEVELOPMENT.

CONTACT THE QPS BUSINESS DEVELOPMENT TEAM TODAY!

CALL +1 512 350 2827 **EMAIL** infobd@qps.com

CUSTOM-BUILT RESEARCH™

QPS Bioanalytical Overview

QPS is a Global CRO with four advanced bioanalytical facilities in the US, Netherlands, Taiwan and India to serve the evolving needs of the Pharmaceutical and Biotech industries. Our scientists come from a variety of backgrounds and can confidently perform the pharmacokinetic (PK), Immunogenecity assessment, pharmacodynamic (PD), and pharmacogenomics (PGx) experiments required by your preclinical or clinical study design. Our staff has considerable experience with conventional matrices (plasma, serum, whole-blood, urine, feces), as well as various animal and human tissues.

Validated Assays

These vast global resources also include a large portfolio of over 800 validated assays, bound to cover your global bioanalysis and clinical study needs. QPS builds robust assays for regulated bioanalysis that are validated in accordance with regulations.

Regulated Bioanalysis

QPS complies with Good Laboratory Practice (GLP) regulations and guidances from the U.S. Food and Drug Administration and other regulatory agencies. QPS also incorporates global GLP principles and regulations for successful submissions, smoothing the way for regulatory acceptance.

Method Development

QPS works with you to develop assays on the most appropriate technology platform. Before any method development work begins, we sit down with you to review and discuss the assay requirements and intended use, such as:

- Lead optimization vs. Candidate Selection vs. Regulated Bioanalysis
- Liquid chromatography–mass spectrometry (LC-MS/MS) for small molecule drug candidates and their potential metabolites
- Ligand Binding Assay (LBA) or LC-MS/MS for peptide and protein drugs
- Ultra-high-performance liquid chromatography coupled to high-resolution mass spectrometry (UHPLC-HRMS) or hybridization-HPLC-fluorescence or HPLC-ultraviolet (UV) or hybridization-LBA for oligonucleotide based drugs
- Reverse Transcription – Quantitative Polymerase Chain
- Reaction (RT-qPCR/qPCR) for mRNA (biotherapeutics and viral or plasmid vectors)

Once the methods, data, and results have been verified, a Quality Assurance Statement is included in every final report.

QPS is a Global CRO with locations around the world